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Do specific types of sleep disturbances represent
risk factors for poorer health-related quality of life
in inflammatory bowel disease? A longitudinal
cohort study
Alexander J. Scott1* , Olivia Flowers1 and Georgina Rowse2
1School of Health & Related Research (ScHARR), University of Sheffield, UK
2Clinical Psychology Unit, Department of Psychology, University of Sheffield, UK
Objectives. Poor global sleep quality is commonly reported in people with inflamma-
tory bowel disease (IBD) and is linked to poorer health-related quality of life (HRQoL).
However, understanding is currently limited by a lack of: (1) longitudinal research and (2)
research investigating the impact of specific types of problems sleeping on IBD-related
outcomes, particularly on HRQoL.
Design. Observational longitudinal cohort study.
Methods. N = 276 participants with IBD completed measures at baseline (T1) and 4
weeks later at T2. Four specific sleep disturbances associated with IBD including sleep
apnoea, insomnia, restless legs, and nightmares were measured alongside depression,
anxiety and stress, and HRQoL.
Results. After controlling for participant demographics and clinical characteristics, T1
depression, anxiety, stress, and T1 HRQoL, more severe symptom severity of sleep
apnoea (B = 0.30, p < .05) and insomnia symptoms (B = 0.23, p < .05) at T1
significantly predicted poorer HRQoL at T2. However, the experience of restless legs
(B = 0.03, p > .87) and nightmares (B = 0.14, p > .11) at T1 did not predict HRQoL.
Conclusion. Symptoms synonymous with sleep apnoea and insomnia might represent
modifiable risk factors that provide independent contributions to HRQoL over time in
those with IBD. These findings suggest that interventions designed to improve sleep
apnoea and insomnia could confer benefits to HRQoL in those with IBD. However, more
longitudinal research is needed to understand the contribution of sleep disturbances over
the longer term, as well as more randomized controlled trials testing the effect of
improving sleep on IBD-related outcomes.
Statement of contribution
What is already known on this subject?
 Poor global sleep quality is commonly reported by those with a diagnosis of inflammatory bowel
disease.
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 Poor global sleep quality is adversely associated with a number of IBD-related outcomes including
quality of life, fatigue, and disease symptom flares.
 However, extant literature has not examined the contribution of specific types of sleep disturbances
to health-related quality of life in IBD over time, instead relying on global measures of sleep, and
largely limited to cross-sectional designs.
What does this study add?
 To our knowledge, this is the first longitudinal study investigating whether specific types of sleep
disturbances known to be associatedwith IBD-relatedoutcomes can predict subsequentHRQoL in
IBD.
 Specific symptoms of sleep apnoea and insomnia (but not restless legs or nightmares) might
represent risk factors for HRQoL over time in those with IBD.
Inflammatory bowel disease (IBD), including the two main diagnoses of Crohn’s disease
(CD) and ulcerative colitis (UC), is a chronic condition characterized by relapsing and
remitting inflammation of the gastrointestinal tract and is a global health concern
(M’Koma, 2013) that has huge implications for both the individuals affected by IBD, and
thehealth care systems chargedwithproviding care (Odes et al., 2006; Park&Bass, 2011).
The pathogenesis of IBD is complex; however, it is accepted to include a combination of
genetic, environmental, and behavioural factors (Ananthakrishnan, 2013, 2015; Xavier &
Podolsky, 2007). Given that the environmental and behavioural risk factors associated
with IBD are more amenable to change, there has been an upsurge in attempts to target
these risk factors as a route to improving IBD and its related outcomes. One such
modifiable behavioural risk factor commonly associated with IBD that has received
attention in recent years is sleep (Ali & Orr, 2014; Ananthakrishnan, 2015; Kinnucan,
Rubin, & Ali, 2013).
Sleep disturbances in IBD
The majority of extant literature investigating the role of sleep in IBD has tended to
measure ‘sleep quality’, which is generally accepted to consist of two domains: (1) sleep
continuity (i.e., getting to sleep and staying asleep through the night) and (2) feeling
refreshed upon waking (Harvey, Stinson, Whitaker, Moskovitz, & Virk, 2008; Libman
et al., 2016). Generally, people living with IBD report poorer self-reported sleep quality
when compared to healthy controls (Iskandar et al., 2020; Keefer, Stepanski, Ranjbaran,
Benson, & Keshavarzian, 2006; Kinnucan et al., 2013; Qazi & Farraye, 2018; Ranjbaran
et al., 2007). Getting good quality sleep is important in its own right. For example, in a
survey of over 8,000people from the general population, goodquality sleepwas the single
biggest contributor to well-being, more than job security, income, and relationship status
(National Centre for Social Research, 2017). However, getting good quality sleepmight be
particularly important for those with IBD, with a handful of longitudinal studies
suggesting that poor sleep quality is associated with poorer clinical outcomes, including
fatigue (Graff et al., 2013) and disease activity (Ananthakrishnan, Long,Martin, Brendel, &
Kappelman, 2013; Uemura et al., 2016). Sleep quality is, therefore, an important and
widely reported constructwithin IBD research.However,measuring overall sleep quality,
and/or its constituent parts, is unable to accurately delineate whether specific types of
sleep disturbance (e.g., insomnia) might be associated with IBD-related outcomes. Given
that peoplewith IBD experience a variety of specific sleep disturbances (Scott, Flowers, &
Rowse, 2020), including symptoms of sleep apnoea (Keefer et al., 2006; Ranjbaran et al.,
2007), insomnia (Hon, 2010; Ranjbaran et al., 2007), restless-leg syndrome (Becker et al.,
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2018; Takahara et al., 2017), and nightmares (Pirinen, Kolho, Simola, Ashorn, & Aronen,
2010; Ranjbaran et al., 2007), it is important that the associations between sleep and IBD
are broken down further, with the study of specific disturbances and IBD outcomes.
Health-related quality of life in IBD and the association with sleep disturbance
One outcome that is particularly affected by IBD is health-related quality of life (HRQoL),
which refers to ‘those aspects of self-perceivedwell-being that are related to or affected by
the presence of disease or treatment’ (Ebrahim, 1995, p. 1384). For example, Devlen et al.
(2014) reported that the symptoms of IBD can provoke both immediate impacts on
HRQoL (e.g., disruption of daily activities, dietary restrictions, lifestyle changes) andmore
distal impacts (e.g., work, school, social and leisure activities, relationships, and
psychological well-being). Given that it is currently not possible to ‘cure’ IBD, the goal
of treatment is often to achieve and maintain control of the disease, thereby optimizing
HRQoL (Bodger, Ormerod, Shackcloth, & Harrison, 2014). Consequently, IBD HRQoL is
an important outcome, to both patients receiving care and to the clinicianswho provide it
(Huppertz-Hauss et al., 2015). However, the finding from a recent meta-analysis that
disease symptomactivity explains only 37%of the variance inHRQoL in thosewithCDhas
led to calls for more research into additional, possibly modifiable determinants of HRQoL
in those with IBD (van der Have et al., 2014). Given that sleep has been shown to be a
modifiable determinant of health in a number of fields (Kyle &Henry, 2017; Kyle, Morgan,
& Espie, 2010), it is possible that sleep might represent a risk factor for HRQoL in those
with IBD. However, only a small number of studies limited by a cross-sectional design and
smaller sample sizes have investigated the association between sleep and IBD HRQoL,
many ofwhich report that that poor sleep quality is associatedwith poorerHRQoL (Habibi
et al., 2017; Keefer et al., 2006; Ranjbaran et al., 2007; Uemura et al., 2016).
The present research
The present research aims to build on extant literature by addressing two key
limitations. Firstly, the majority of extant literature has focussed on measuring overall
sleep quality; therefore, it is unclear whether specific types of problems sleeping might
be more or less associated with IBD-related outcomes. Given that different types of
sleep disturbances have different screening methods (Devine, Hakim, & Green, 2005;
Iba~nez, Silva, & Cauli, 2018; Marino et al., 2013) and treatment strategies (Hansen,
H€ofling, Kr€oner-Borowik, Stangier, & Steil, 2013; Harrison, Keating, & Morgan, 2019;
Iftikhar et al., 2017; Zachariae, Lyby, Ritterband, & O’Toole, 2016), understanding
whether specific types of sleep disturbances are predictive of HRQoL in IBD could
facilitate suggestions that health care services should be doing more to screen for and
subsequently treat sleep disturbances as part of routine care (Almedimigh et al., 2018;
Green et al., 2017; Kinnucan et al., 2013; Sofia et al., 2018). Secondly, no study has
examined the temporal relationship between specific sleep disturbances and HRQoL in
those with IBD over time. In an effort to address these limitations, we will measure
specific types of sleep disturbances that previous literature has suggested are associated
with IBD including symptoms of sleep apnoea, insomnia, restless legs, and nightmares.
Then, we will test whether these sleep disturbances can predict HRQoL 4 weeks later.
We hypothesize that baseline symptoms of these sleep disturbances will all predict
HRQoL at follow-up.
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Method
Study design
The present research adopted a longitudinal cohort design. Participants completed self-
reported measures. All measurements were taken online at baseline (T1) and then again
4 weeks later (T2). Ethical approval for this researchwas provided by the Research Ethics
Committee based within the School of Health and Related Research (ScHARR), at the
University of Sheffield.
Participants
Participants were recruited from two sources: (1) through the ‘Crohn’s and Colitis UK’
charity website, and (2) from online support groups for those living with IBD. Enrolment
to the study began in May 2017 and concluded in July 2017. The inclusion criteria for the
present research required participants to be: (1) over the age of sixteen (so that consent
could be obtained from the participant alone), and (2) have a diagnosis of IBD.
Participants not meeting these two criteria, not providing explicit electronic consent,
those who did not provide a follow-up email address so their responses could be linked
at T2, and those who did not start the baseline surveys were excluded from the present
study.
Measures
Demographic and clinical characteristics
Participants were asked their age and gender, as well as items pertaining to their IBD
including their IBDdiagnosis type, age at IBDdiagnosis, number of years livingwith an IBD
diagnosis, number of IBD-related hospital admissions in the past year, whether they had
ever undergone IBD-related surgery, current and/or previous use of a stoma, andwhether
theywere currently takingmedication for their IBD. Additionally, participantswere asked
whether they were currently receiving psychological therapy and/or medication for a
mental health or sleep-related problem. These variables were chosen to not only describe
the characteristics of the sample, but also because they are characteristics that might be
associated with sleep, depression, anxiety, stress, and HRQoL (and therefore might
require controlling for in the analyses).
The Sleep-50 Questionnaire
The Sleep-50was used tomeasure symptoms of four types of sleep disturbance, including
symptoms of (1) sleep apnoea (e.g., ‘I’m sometimes short of breathwhen Iwake upduring
the night’); (2) insomnia (e.g., ‘I find it difficult to fall asleep’); (3) restless legs (e.g., ‘I
cannot keep my legs still when I’m falling asleep’); and (4) nightmares (e.g., ‘I have
frightening dreams’). Participants are asked the extent to which each item has applied to
them over the previous 4 weeks on a 4-point scale ranging from 1 (not at all) to 4 (very
much), with higher scores indicating more severe sleep disturbance. The Sleep-50 has
been validated for use in both the general population and those with clinically defined
sleep complaints (Spoormaker, Verbeek, van den Bout, & Klip, 2005). Internal reliability
in the present research was acceptable for the sleep apnoea (a = 0.72), and restless legs
subscales (a = 0.76), good for the insomnia subscale (a = 0.87), and excellent for the
nightmares subscale (a = 0.94).
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The Short Form Depression, Anxiety, Stress Scale (DASS-21)
Depression, anxiety, and stress were measured using the 21-item short form of the
Depression, Anxiety, and Stress Scale (DASS-21). Participants are asked to indicate on a 4-
point scale ranging from 0 to 3, the extent towhich they agreedwith statements assessing
facets of negative affect over the pastweek. For example, seven statements are concerned
with feelings of depression (e.g., ‘I couldn’t seem to experience any positive feeling at
all’). A further seven statements ask participants about feelings of anxiety (e.g. ‘I was
aware of the actionofmyheart’). Finally, seven statements aim to explore feelings of stress
(e.g. ‘I was intolerant of anything that keptme from getting on’). The lowest possible total
score on the DASS-21 is 0, through to 63, with higher scores indicating higher levels of
negative affect.
To calculate severity cut-offs for the DASS-21, total scores for each subscale were
multiplied by two (so that scores are comparable to the DASS-42, Ng et al., 2007), and cut-
offs suggested by Lovibond and Lovibond (1995) were used to assign a qualitative index.
For total depression, the ‘normal’ range = 0–9, ‘mild’ = 10–13, ‘moderate’ = 14–20,
‘severe’ = 21–27, and ‘extremely severe’ = 28+. For total anxiety, the ‘normal’
range = 0–7, ‘mild’ = 8–9, ‘moderate’ = 10–14, ‘severe’ = 15–19, and ‘extremely sev-
ere’ = 20+. For total stress, the ‘normal’ range = 0–14, ‘mild’ = 15–18, ‘moderate’ = 19–
25, ‘severe’ = 26–33, and ‘extremely severe’ = 34+. The DASS-21 has been validated for
use in both clinical and non-clinical populations and has been found to be a reliable and
valid measure of negative affect (Henry & Crawford, 2005). In the present research,
internal reliabilitywas excellent for the depression scale (a = 0.93) and good for the stress
(a = 0.87), and anxiety scales (a = 0.82).
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
The SIBDQ is a 10-itemmeasure of the HRQoL of thosewith IBD and is comprised of items
derived from its longer form, the Inflammatory Bowel Disease Questionnaire (IBDQ,
Guyatt et al., 1989). The SIBDQ measures four domains of IBD HRQoL: (1) bowel
symptom frequency (e.g., ‘how often during the last 2 weeks have you been troubled by
pain in the abdomen?’), (2) social aspects (e.g., ‘how often during the last 2 weeks have
you had to delay or cancel a social engagement because of your bowel problem?’), (3)
systemic (e.g., ‘overall, in the last 2 weeks, how much of a problem have you had
maintaining or getting to the weight you would like to be?’, and (4) emotional (e.g., ‘how
much of the time during the last 2 weeks have you felt angry as a result of your bowel
problem?’). Participants are asked to rate the extent to which each item has applied to
themover the last 2 weeks using a 7-point scale,where 1 = all of the time and 7 = none of
the time. Total scores range from 10 to 70, with lower scores indicating more impaired
IBD HRQoL. The SIBDQ is a valid and reliable measure of HRQoL in those with IBD
(Jowett, Seal, Barton, & Welfare, 2001). Internal reliability of the SIBDQ in the present
research was good (a = 0.81).
Approach to analysis
Hierarchicalmultiple linear regression analysiswas conducted using SPSS v25 (IBM, 2017)
to test whether symptom severity of sleep apnoea, insomnia, restless legs, and/or
nightmares at T1 could predict HRQoL 4 weeks later at T2 (while controlling for T1
depression, anxiety, stress, and HRQoL).
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Variables included in the analysis
The dependent variable in the present research was HRQoL as measured by the SIBDQ at
T2. The independent variables included in the analysis were T1 symptoms of sleep apnoea,
insomnia, restless legs, and nightmares. The analysis also included a number of covariates
likely to confound the relationship. Firstly, any T1 participant demographic of clinical
characteristic variable that significantly correlatedwith the independent and/or dependent
variables in the model were entered as covariates, including age, gender, number of years
living with an IBD diagnosis, diagnosis type (CD or UC), and the number of IBD-related
hospital admissions in the last year. Secondly, given that depression, anxiety, and stress are
associated with both sleep disturbances (Alvaro, Roberts, & Harris, 2013; Baglioni et al.,
2011; Taylor, Lichstein, Durrence, Reidel, & Bush, 2005), and HRQoL (Darchia et al., 2018;
Kyle et al., 2010; Lee et al., 2009), depression, stress, and anxiety at T1 were entered as a
covariate in themodel. Finally, it is likely thatT1HRQoLwill be the strongestpredictor of T2
HRQoL; therefore, T1 HRQoL was entered as a covariate in the model.
Sample size calculations
Sample size calculations were performed using G*Power 3.1 (Faul, Erdfelder, Lang, &
Buchner, 2007). To detect a small- to-medium-sized effect with 80% power, a significance
threshold of p < .05, a minimum sample size of N = 250 was required.
Results
Participants and missing data
Figure 1 describes the flowof participants through the study.N = 498 participants began
the online eligibility and consent procedures, of whichN = 16 did not meet the inclusion
criteria (N = 9 under 16 years old, N = 7 had no IBD diagnosis), N = 22 did not provide
consent, N = 29 did not provide an email address, and N = 22 did not start the online
survey (total excluded, N = 89, 17.87%). Consequently, a total of N = 409 participants
provided data at T1. Of these 409 participants at T1, missing data were low. There were
almost no missing data for any of the demographic and clinical characteristic variables,
except for the number of IBD-related hospital admissions in the previous year where
N = 4 (1%) participants provided nodata. Furthermore, therewere nomissing data on any
of the sleep outcomes at T1. For depression, anxiety, and stress at T1, N = 19 (5%)
participants did not provide data, while N = 25 (6%) of participants did not provide
HRQoL data. At T2, N = 121 (30%) were lost to follow-up, leaving a total of N = 288 who
provided data at T2. Of these 288 participants, there were no missing data on sleep
outcomes, and only N = 2 participants did not provide data for depression, anxiety, and
stress, while N = 3 participants did not complete the HRQoL measure.
To test whether any baseline variables could predict subsequent loss to follow-up, we
entered T1 demographic variables, sleep apnoea, insomnia, restless legs, and nightmares,
as well as T1 depression, anxiety, and stress, and T1 HRQoL as independent variables into
a logistic regressionmodel,with loss to follow-up (coded as either yes or no) entered as the
dependent variable. No T1 variable significantly predicted loss to follow-up at T2 at the
p < .05 level. Furthermore, Littles MCAR test revealed that data were missing completely
at random at both T1 (X2(368) = 326.98, p = .94) and T2 (X2(71) = 74.76, p = .36).
Consequently, we are confident that the data observed at T2 are representative of the data
at T1 and are unlikely subjected to attrition bias.
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Descriptive statistics
Participant demographics and clinical characteristics can be seen in Table 1. Table 2
displays descriptive statistics for symptoms of sleep apnoea, insomnia, restless legs, and
nightmares along with mean symptom severity scores exceeding the clinical severity
thresholds1 for the Sleep-50 subscales proposed by Spoormaker et al. (2005). In order to
display possible overlap between the Sleep-50 subscales, Table S1 displays theproportion
of participantswho exceeded the suggested clinical severity thresholds onmore than one
Sleep-50 domain. Table 3 displays descriptive statistics for the depression, anxiety, and
stress scale. Finally, Table 4 displays descriptive statistics for total HRQoL as measured by
the SIBDQ, as well as the systemic, bowel, social, and emotional subscales. We are not
aware of any formal, validated normative values or cut-offs for the SIBDQ. However, to
help contextualize HRQoL in the present sample, Swart, Wellsted, Lithgo, Price, and
Johnson (2013) reported a mean HRQoL score of M = 48 (95% CI = 46.6 to 49.4) from
2,400 IBD participants in the UK. Therefore, HRQoL in the present sample was lower
(worse) in comparison.
Figure 1. CONSORT diagram describing the flow of participants through the study.
1 It is important to note that exceeding the symptom severity threshold does not equate to a clinical diagnosis of a given sleep
disorder, it simply means the participant is experiencing clinically substantive symptoms (that may or may not confer a clinical
diagnosis). Diagnosis requires an assessment of the duration of symptoms, and the impact of symptoms on daily functioning that
was not possible in the present research.
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Assumption checks
Visual inspection of a scatter plot of the residuals suggested that the homoscedasticity
assumption was met (i.e., residuals were randomly distributed with no clear pattern).
Additionally, inspect of theQ-Q plot and histogram suggested that the dependent variable
(i.e., HRQoL at T2) was normally distributed, and levels of skewness (0.01) and kurtosis
(0.95) were low. Furthermore, collinearity of independent variables was not a concern
as evidenced by Tolerance and VIF statistics falling within the acceptable ranges
(tolerance ranged from 0.29 to 0.94, VIF ranged from 1.07 to 3.51). Taken together, the
data used for the present analysis meet the statistical assumptions of hierarchical multiple
linear regression.
Table 1. Demographic and clinical characteristics at T1 and T2
Continuous variables
T1 (N = 409) T2 (N = 276)
M SD M SD
Age 33.86 11.57 33.48 11.36
Years living with IBD diagnosis 9.12 8.52 8.69 8.21
IBD-related hospital admissions in past year 1.62 3.92 1.51 3.82
Categorical variables N % N %
Gender
Male 74 18 55 20
Female 335 82 221 80
IBD diagnosis
Ulcerative Colitis (UC) 155 38 105 38
Crohn’s Disease (CD) 254 62 171 62
Previous IBD-related surgery
Yes 172 42 114 41
No 237 58 162 59
Current stoma
Yes 58 14 42 15
No 351 86 234 85
Using immunosuppressant medication
Yes 259 63 174 63
No 150 37 102 37
Medication for problems sleeping
Yes 96 24 52 19
No 313 76 224 81
Therapy for problems sleeping
Yes 21 5 14 5
No 388 95 262 95
Medication for mental health problems
Yes 148 36 94 34
No 261 64 182 66
Therapy for mental health problems
Yes 71 17 46 17
No 338 83 230 83
Notes. IBD = inflammatory bowel disease.
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Do specific sleep disturbances at T1 predict HRQoL at T2?
Bivariate correlations between T1 sleep disturbances and T2 HRQoL can be seen in
Table 5. Based on a final analysisN of 276 participants, we fit a hierarchicalmultiple linear
regression model to the data (see Table 6 for an analysis summary). T1 sleep apnoea,
insomnia, restless legs, and nightmares were entered as independent variables into block
1. Participant demographic and clinical characteristics that significantly correlated with
T1 sleep parameters, and/or HRQoL at T2were entered into block 2 as covariates. Finally,
T1 severity of depression, anxiety, and stress, along with T1 HRQoL were entered into
block 3 as covariates (for a breakdownof eachmodel analysis step, see Table S2). The final
model described in Table 6 was statistically significant (F(13, 262) = 48.77, p < .001),
and able to explain 69% of the variance in T2 HRQoL.
T1 symptom severity of sleep apnoea (B = 0.30, p < .05) and insomnia (B = 0.23,
p < .05)was significant predictors of HRQoL at T2. However, T1 restless legs (B = 0.03,
p> .87) and severity of nightmares (B = 0.14,p > .11)werenot significant predictors of
T2 HRQoL. These results suggest that even after controlling for T1 depression, stress, and
anxiety, aswell as T1HRQoL, every unit increase in sleep apnoea severity and/or insomnia
at T1 was associated with a 0.30 and 0.23 unit decrease in HRQoL at T2 (i.e., HRQoL
worsened).
Sensitivity analyses
We conducted a sensitivity analysis to explore whether possible overlap between the
depression, anxiety, and stress scales and the emotional domain of the SIBDQ impacted
the study findings. Correlations between the emotional subdomain of the SIBDQ and the
depression (r = .52, p < .01), anxiety (r = .43, p < .05), and stress (r = .39,
p < .01) scales were statistically significant and in the small- to-medium-sized range. We
Table 2. Symptom severity of sleep disturbances measured by the Sleep-50 for participants providing
data at T1 and T2
Variable
Time 1 (N = 276) Time 2 (N = 276)
M SD
Cut-off exceededa,b
N (%)
M SD
Cut-off exceededa,b
N (%)
Yes No Yes No
Sleep apnoea 15.24 4.01 141 (51) 135 (49) 15.17 3.90 142 (51) 134 (49)
Insomniac 20.34 5.87 161 (58) 115 (42) 19.88 5.46 152 (55) 124 (45)
Restless legs 7.04 2.77 132 (48) 144 (52) 7.21 2.85 141 (51) 135 (49)
Nightmares 8.38 5.62 25 (9) 251 (91) 8.72 5.65 25 (9) 251 (91)
Notes. aCut-off thresholds proposed by Spoormaker et al. (2005) for total scores on the Sleep-50
subscales were used to determine the proportion of participants experiencing ‘clinically substantive’
symptoms of sleep apnoea (total subscale score ≥ 15), insomnia (≥19), restless legs (≥ 7), and nightmares
(score ≥ 3 on item 32 and total sum score ≥ 9 on items 33, 34, and 35); bPlease note that exceeding the
threshold does not equate to a clinical diagnosis of a given sleep disorder, it simply means the participant is
experiencing clinically substantive symptoms. Diagnosis requires an assessment of duration of symptoms
and impact on daily function that was not possible in the present research; cDifferences between T1 and
T2 on this variable were statistically significant (p < .05) based on those who provided data at both time
points.
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reran the regression analysis described abovewithout the emotional subdomain included
in the total IBDHRQoL score, and results remained largely the same. T1 symptom severity
of sleep apnoea (B = 0.28, p < .05) and insomnia (B = 0.24, p < .01) was significant
predictors of HRQoL at T2 (minus the emotional impact domain). Similarly, T1 restless
Table 3. Descriptive statistics for the depression, anxiety, and stress scales for participants providing
data at T1 and T2
Time 1 (N = 276) Time 2 (N = 276)
M (SD) N (%) M (SD) N (%)
Total depressiona 7.87 (5.71) 7.43 (5.86)
Normal range 92 (33) 112 (41)
Mild range 38 (14) 23 (8)
Moderate range 62 (22) 66 (24)
Severe range 33 (12) 28 (10)
Extremely severe range 51 (18) 47 (17)
Total anxiety 6.66 (4.85) 6.37 (4.61)
Normal range 95 (34) 101 (37)
Mild range 22 (8) 17 (6)
Moderate range 48 (17) 63 (23)
Severe range 36 (13) 29 (11)
Extremely severe range 75 (27) 66 (24)
Total Stressa 9.12 (4.88) 8.66 (5.05)
Normal range 110 (40) 124 (45)
Mild range 43 (16) 44 (16)
Moderate range 55 (20) 47 (17)
Severe range 44 (16) 39 (14)
Extremely severe range 24 (9) 22 (8)
Notes. Please see the ‘The Short Form Depression, Anxiety, Stress Scale (DASS-21)’ description in the
measures section of the method for more detail on how cut-offs were assigned.
aDifferences between T1 and T2 on this variable were statistically significant (p < .05) based on those
who provided data at both time points.
Table 4. Descriptive statistics for the short inflammatory bowel disease questionnaire for participants
providing data at T1 and T2
SIBDQ scores
T1 (N = 276) T2 (N = 276)
M SD Min Max M SD Min Max
Total HRQoLa 40.56 11.40 16 72 42.17 12.26 15 66
Systemica 6.36 2.89 2 14 6.68 3.15 2 14
Bowela 12.09 4.35 3 21 12.55 4.34 3 21
Sociala 9.21 4.29 2 16 9.75 4.40 2 16
Emotionala 12.90 2.65 7 21 13.19 2.78 4 20
Notes. T1 = time 1; T2 = time 2 (4 weeks after T1); M = mean; SD = standard deviation; Min = min-
imum score; Max = maximum score; HRQoL = health-related quality of life; SIBDQ = Short Inflam-
matory Bowel Questionnaire.
aDifferences between T1 and T2 on this variable were statistically significant (p < .05) based on those
who provided data at both time points.
10 Alexander J. Scott et al.
legs (B = 0.12, p = .474) and severity of nightmares (B = 0.09, p = .268) were still
not significant predictors. Consequently, although there was some overlap between the
depression, anxiety, stress scale, and the emotional domain of the SIBDQ, this did not
change interpretation of the findings.
Discussion
The present research aimed to test whether baseline symptoms of four specific types of
sleep disturbances known to be associated with IBD could predict HRQoL 4 weeks later.
We found that baseline symptom severity of both sleep apnoea and insomnia was
Table 5. Bivariate correlations between T1 sleep parameters and T2 health-related quality of life for
participants included in the regression analysis (N = 276)
1 2 3 4 5
1. T1 apnoea 1 .44** .52** .36** .37**
2. T1 insomnia 1 .41** .42** .43**
3. T1 restless legs 1 .41** .39**
4. T1 nightmares 1 .33**
5. T2 HRQoL 1
Notes. HRQoL = health-related quality of life.
**p < .01.
Table 6. Results of the hierarchical linear regressionwith HRQoL at T2 as the dependent variable (total
analysis N = 276)
Variable B SE 95% CI (B) b t p
Sleep disturbances at T1
Sleep apnoea* 0.30 0.15 0.59 to 0.01 0.10 1.99 .048
Insomnia* 0.23 0.10 0.42 to 0.03 0.11 2.31 .022
Restless legs 0.03 0.19 0.41 to 0.34 0.01 0.16 .872
Nightmares 0.14 0.09 0.32 to 0.04 0.07 1.56 .121
Covariates at T1
Depression** 0.32 0.11 0.54 to 0.09 0.15 2.78 .006
Anxiety* 0.37 0.15 0.67 to 0.07 0.15 2.45 .015
Stress*** 0.56 0.16 0.87 to 0.25 0.22 3.55 <.001
HRQoL*** 0.69 0.05 0.60 to 0.79 0.65 14.24 <.001
Age 0.03 0.05 0.06 to 0.12 0.03 0.75 .456
Gender 1.32 1.10 3.48 to 0.85 0.04 1.20 .232
Year with IBD diagnosis 0.09 0.06 0.21 to 0.03 0.06 1.51 .133
Diagnosis type 0.34 0.88 2.07 to 1.39 0.01 0.39 .699
Hospital admissions 0.17 0.12 0.07 to 0.40 0.05 1.41 .159
Note. Data reported are: B = unstandardized coefficient, SE = standard error, 95% CI (B) = 95%
confidence intervals for standardized regression coefficient, b = standardized regression coefficient.
T1 = time 1; T2 = time 2; HRQoL = health-related quality of life; IBD = inflammatory bowel disease.
*p < .05; **p < .01; ***p < .001.
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significant predictors ofHRQoL 4 weeks later, even after controlling for demographic and
clinical characteristics, depression, stress, and anxiety, and importantly baseline HRQoL.
However, although previous research has shown that peoplewith a diagnosis of IBDoften
report troubling symptoms of restless legs and nightmares (Becker et al., 2018; Keefer
et al., 2006; Pirinen et al., 2010; Ranjbaran et al., 2007; Scott et al., 2020; Takahara et al.,
2017), we found that these sleep disturbanceswere not predictive of subsequent HRQoL.
In terms of possible explanations for this, the experience of nightmares at T1 was
significantly associated with T2 HRQoL in each model until T1 HRQoL was added to the
model as a covariate, suggesting that the experience of nightmares was unable to account
for variance inHRQoL at T2 above and beyond T1HRQoL.However, symptoms of restless
legs were never able to predict T2 HRQoL, even in block 1 where only the other sleep
parameters were included in themodel (see Table S2). This might suggest that symptoms
of restless legs were unable to explain variance in T2 HRQoL above and beyond the
variance explained by insomnia, sleep apnoea, and nightmares. However, it is important
to note that the present researchmeasured symptoms of four types of sleep disturbance in
one sample. Although bivariate associations between sleep parameters were only in the
small- to-medium-sized range, there was still some overlap between sleep parameters that
might have impacted results (see also Table S1). Consequently, it is possible that
symptoms of restless legs and nightmares, if measured in isolation from other sleep
disturbances, might predict HRQoL in those with IBD, especially in those with clinically
defined restless legs and nightmares.
Sleep apnoea and insomnia as modifiable treatment targets
The findings presented here suggest that symptoms of insomnia and sleep apnoea might
represent a risk factor for worse HRQoL (at least in the short term). Therefore, by
reducing these sleep disturbances, we might expect that future HRQoL could be
improved. The notion that improving a given sleep disturbance might lead to
improvements in wider health has been applied to other areas of health (although not
yet in IBD), with research generally demonstrating a benefit of improving sleep on both
physical (Heckler et al., 2016; Roehrs, 2009; Smith et al., 2015; Vitiello, Rybarczyk, Von
Korff, & Stepanski, 2009) and mental health outcomes (Christensen et al., 2016;
Freeman et al., 2017; Scott, Webb, & Rowse, 2017). However, the application of
improving sleep to IBD-related outcomes lags behind other fields. Therefore, it is unclear
which types of interventions might be most effective for sleep disturbances in IBD and
whether ‘off the shelf’ interventions for sleep disturbances might need adapting towards
the needs of those with IBD. For example, cognitive behavioural therapy for insomnia
(CBTi) is an effective treatment approach for insomnia (Ho et al., 2015; van Straten et al.,
2018) and has demonstrated success in those with physical and mental health
comorbidities (Wu, Appleman, Salazar, & Ong, 2015). However, given that people with
IBD often experience physical symptoms that interfere with getting a good night’s sleep
(e.g., abdominal pain, needing to use the toilet), as well as an increased prevalence of
mental health difficulties (Brooks et al., 2019; Tribbick et al., 2015) that are often
associated with more problems sleeping, it is important that CBTi for those with IBD
accounts for this. We recommend that future research should focus on conducting high-
quality randomized controlled trials testing the effect of interventions designed to
improve sleep, particularly insomnia and sleep apnoea, on subsequent IBD HRQoL.
Doing so will not only provide an evidence base fromwhich clinicians and policy makers
can identify effective interventions to improve sleep disturbances in IBD (an area that is
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currently lacking), but will also provide a robust causal test of the role of sleep
disturbances in the trajectory of HRQoL (Cartwright, 2010).
The present research is the first (to our knowledge) to report the prospective
association between specific sleep disturbances and HRQoL in those with IBD.
However, it is important to note that evidence that poor sleep can predict HRQoL does
not preclude the reverse direction and that more impaired HRQoL is likely to also lead
to more problems sleeping (i.e., a bidirectional relationship). Indeed, given that the
relationship between sleep and health and well-being has been shown to be
bidirectional in non-IBD populations (Alsaadi et al., 2014; Alvaro et al., 2013; Bartlett
& Jackson, 2016; Lee, Buxton, Andel, & Almeida, 2019; Van Dyk, Thompson, & Nelson,
2016), it is likely that the relationship between sleep and IBD HRQoL is also
bidirectional. The present research was unable to inform the bidirectional nature of this
relationship; therefore, future research might consider developing the present study by
examining the bidirectional relationship between specific sleep disturbances and
HRQoL so that the relationship can be better understood. Furthermore, because the
present study did not measure IBD symptom activity directly, it is difficult to rule out
that the symptoms of IBD itself might be a common cause of both lower HRQoL and
problems sleeping simultaneously. Although disease symptom activity has been shown
to contribute only 37% of the variance in IBD HRQoL (van der Have et al., 2014), and
the bowel symptom subscale of the SIBDQ (which correlates strongly with disease
activity, Jowett et al., 2001) was entered as a covariate in the regression model as part
of the HRQoL total score, future research should consider employing a more direct
measure of IBD symptom activity so that the independent effect of insomnia and sleep
apnoea might be better isolated.
The importance of screening for specific sleep disturbances in routine care
The present findings suggest that the routine care of those with IBD could consider
incorporating assessments to screen for the presence of specific types of sleep
disturbances (particularly insomnia and sleep apnoea). However, the routine manage-
ment of sleep disturbances in IBD is not common place, and part of the problemmight be
the lack of clear guidance on screening and treating sleep disturbances. For example,
there are many types of screening tools that can be either self-reported by participants or
objectively measured using technology that can be used to detect sleep disturbances
ranging from global measures of sleep quality, to tools to detect specific sleep
disturbances like insomnia and sleep apnoea. Currently, there are few guidelines for
the management of sleep disturbances in IBD (National Insititute for Health & Care
Excellence, 2019a, 2019b), meaning patients and professionals might lack the informa-
tion they need to make informed decisions around how to detect sleep disturbances (and
therefore how to treat sleep disturbances). Consequently, we recommend that future
research should consider investigating the possible barriers to the routinemanagement of
sleep disturbances in IBD from both the perspectives of health care professionals and
patients. Doing so will allow the identification of factors that preclude the effective
management of sleep so that they can be ameliorated.
Limitations
Firstly, recruitment to the present researchwas based on self-reported IBD diagnosis from
a national IBD charity and online IBD support groups. Although Randell et al. (2014)
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reported that agreement between self-reported diagnosis and clinician confirmation of
diagnosis is high at 97% (see also Kelstrup, Juillerat, & Korzenik, 2014), future research
might seek to include clinically confirmed IBD cases. Secondly, although there is evidence
that IBD is more prevalent in females (Brant & Nguyen, 2008), and the present research
controlled for gender in the analysis, the majority of the sample were female; therefore,
the representativeness of the present findings to male IBD populations could be
considered limited. Finally, thepresent research employed a single, relatively short follow-
up period of 4 weeks. It would be interesting for future research to conduct similar
studies usingmultiple, longer follow-up durations so that the impact of problems sleeping
on long-termHRQoL in IBD can be better understood, as well as examining a bidirectional
association between sleep and HRQoL. Indeed, little is known about the trajectory of
sleep disturbances experienced by those with IBD in general, and being able to better
characterize the nature and course of sleep disturbances in IBDwould be a useful addition
to the literature.
Conclusion
In conclusion, the present research suggests that higher symptom severity of sleep
apnoea and insomnia (but not restless legs or nightmares) is longitudinally associated
with poorer HRQoL in those with IBD. These findings suggest that experiences of sleep
apnoea and insomnia could represent modifiable behavioural treatment targets in
addition to routine IBD care that could confer particular benefits to the HRQoL.
However, future research might consider examining the temporal relationship between
sleep disturbances and HRQoL over longer time periods than those reported here so
that the trajectory of sleep disturbances, and their impact on IBD outcomes can be
better understood over the longer term. We believe the next appropriate steps in the
field are to test whether interventions designed to improve sleep, particularly symptoms
of sleep apnoea and insomnia, are not only able to improve sleep in those with IBD, but
also whether any improvement in sleep leads to improvements in IBD-related outcomes
such as HRQoL.
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